BTIG Reiterates Neutral Rating on Senseonics Holdings (SENS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls 1% as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Stifel Reiterates Buy Rating on Senseonics Holdings (SENS)
September 17, 2024 8:29 AM EDTStifel analyst Mathew Blackman reiterated a Buy rating and $2.50 price target on Senseonics Holdings (NYSE: SENS).
The analyst comments "This morning, SENS announced on-time FDA approval of Eversense 365-day with iCGM status; a 4Q24 US launch timeline was also re-affirmed. Importantly, approval... More
Senseonics: Eversense 365 Receives FDA Clearance
September 17, 2024 7:04 AM EDTSenseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, today announced that the US Food and Drug Administration (FDA) has cleared the next-generation Eversense® 365 CGM system for people with Type 1 and Type 2 diabetes aged 18 years and older. Eversense 365 is the worlds first One Year CGM system, representing a significant breakthrough in diabetes technology and management.
The approval of Eversense 365 represents a significant leap in... More
